SLRX:NSD-Salarius Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.7705

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.02M

Analyst Target

USD 4.43
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
SMMT Summit Therapeutics PLC

N/A

USD 27.07B
RPRX Royalty Pharma Plc

N/A

USD 18.40B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing SLRX

SRET Global X SuperDividend® .. 3.56 % 0.59 %

N/A

USD 0.18B
REM iShares Mortgage Real Est.. 3.19 % 0.48 %

N/A

USD 0.55B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -58.13% 15% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.13% 15% F 8% B-
Trailing 12 Months  
Capital Gain -80.09% 18% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.09% 18% F 7% C-
Trailing 5 Years  
Capital Gain -99.67% 6% D- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.67% 6% D- 2% F
Average Annual (5 Year Horizon)  
Capital Gain 92.12% 84% B 93% A
Dividend Return 92.12% 84% B 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 893.66% 12% F 4% F
Risk Adjusted Return 10.31% 63% D 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.